LEGN
Companies
NASDAQ
Legend Biotech Corporation
Health Care
$33.99
+$1.45 (+4.46%)
Price Chart
Overview
About LEGN
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Market Cap
$8.3B
Volume
71.2M
Avg. Volume
57.3M
P/E Ratio
-41.46269
Dividend Yield
0.00%
Employees
1.3K
Company Information
Latest News for LEGN
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
April 8, 2025
Mizuho's Jared Holz details potential biotech, pharma acquisitions
June 4, 2025
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet
May 2, 2025
Risk & Correlation Analysis
Market Correlation
0.57
Low Correlation
Volatility
High (0.47)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, LEGN shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$8.3B
Volume71.2M
P/E Ratio-41.46
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025